Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Man, G.
Right arrow Articles by Sproule, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Man, G.
Right arrow Articles by Sproule, B.

Chest, Vol 90, 832-836, Copyright © 1986 by American College of Chest Physicians

ARTICLES

Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease

GC Man, K Hsu and BJ Sproule

To evaluate the efficacy of a mild anxiolytic, alprazolam, in relieving dyspnea, we conducted a randomized, placebo-controlled double-blind study on patients with chronic obstructive lung disease. Twenty-four patients had alprazolam (0.5 mg bid) or placebo administered for one week, followed by placebo for one week, then either placebo or alprazolam for the third week. Assessment tests were performed at the outset, end of the first and second weeks, and finally end of the third week. The parameters measured were: pulmonary function, exercise testing on a bicycle ergometer, and the distance covered in a 12 minute walk. Subjective sensations of dyspnea at rest and during guarded exercise, as well as subjective feelings of calmness or anxiety were also recorded. There was no difference in mechanical lung function, but the PO2 tended to decrease and PCO2 to increase after alprazolam administration. The maximum exercise level attained and the distance covered in the 12 minute walk was unchanged. The subjective perception of dyspnea was the same before and after alprazolam, at rest and during exercise. We conclude that alprazolam is not effective in relieving exercise dyspnea in patients with obstructive lung disease.


This article has been cited by other articles:


Home page
 ChestHome page
G. A. Silvestri, C. Sherman, T. Williams, S.-S. Leong, P. Flume, and A. Turrisi
Caring for the Dying Patient With Lung Cancer*
Chest, September 1, 2002; 122(3): 1028 - 1036.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. Meek
Dyspnea . Mechanisms, Assessment, and Management: A Consensus Statement
Am. J. Respir. Crit. Care Med., January 1, 1999; 159(1): 321 - 340.
[Full Text]

Home page
 PsychosomaticsHome page
J. W. Smoller, M. H. Pollack, D. Systrom, and R. L. Kradin
Sertraline Effects on Dyspnea in Patients With Obstructive Airways Disease
Psychosomatics, February 1, 1998; 39(1): 24 - 29.
[Abstract] [Full Text]

Home page
 PediatricsHome page
W. M. Robinson, S. Ravilly, C. Berde, and M. E. Wohl
End-of-Life Care in Cystic Fibrosis
Pediatrics, August 1, 1997; 100(2): 205 - 209.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. T. Ferguson and R. M. Cherniack
Management of Chronic Obstructive Pulmonary Disease
N. Engl. J. Med., April 8, 1993; 328(14): 1017 - 1022.
[Full Text]

Home page
 AM J HOSP PALLIAT CAREHome page
L. W. Horn
Terminal dyspnea: A hospice approach
American Journal of Hospice and Palliative Medicine, March 1, 1992; 9(2): 24 - 32.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American College of Chest Physicians.